What Is Retatrutide 40mg (R&D Only)?
Retatrutide 40mg (R&D Only) is the sustained-phase research-grade triple GLP-1/GIP/Glucagon receptor agonist compound supplied by Alluvi Healthcare — Britain’s most trusted domestic source for retatrutide UK R&D supply. Delivering 40mg of research-grade retatrutide across 4×10mg doses in a precision pre-filled pen format, this is the definitive sustained-phase R&D compound for UK laboratories requiring higher-dose, extended-timeline triple-agonist research protocols that the Retatrutide 20mg (R&D Only) initiation format cannot power alone.
Retatrutide 40mg — also referenced in UK research communities as reta pen, retratrutide, reta uk, reta jab, alluvi reta pen and alluvi retatrutide — represents the highest-dose pre-filled retatrutide format available from a UK domestic source. At 4×10mg doses with 2.5mg micro-dose precision increments, it provides UK researchers with the full compound volume required for multi-administration study designs, dose-escalation protocols, sustained metabolic biology investigations and comprehensive comparative triple vs dual agonist research programmes. UK researchers looking to buy retatrutide UK at the highest dose from the most verified source will find everything they need at Alluvi Healthcare.
The Science — Why Retatrutide 40mg is the Gold Standard for UK R&D
Retatrutide’s triple-receptor architecture — simultaneously engaging GLP-1, GIP and Glucagon receptor systems — produces a uniquely broad metabolic research profile that no dual agonist can replicate. At 40mg across 4×10mg doses, the Retatrutide 40mg (R&D Only) pen enables UK researchers to investigate the full sustained-phase expression of this triple-agonist pharmacology — including dose-dependent energy expenditure increases, sustained adipose tissue lipolysis, hepatic fat oxidation across extended experimental timelines, and the complete multi-administration pharmacokinetic profile that four doses make possible.
The landmark Phase 2 retatrutide clinical trial published in the New England Journal of Medicine (Jastreboff et al., 2023) demonstrated dose-dependent weight reductions of up to 24.2% at 48 weeks — a figure that surpassed every previously published pharmacological weight reduction in clinical trial history at the time of publication. The highest-dose groups in this trial — analogous to the 40mg R&D format — demonstrated the most pronounced outcomes across all efficacy endpoints, providing direct research justification for the Retatrutide 40mg R&D format as the preferred sustained-phase compound for UK metabolic research programmes. Full literature available on PubMed and the ClinicalTrials.gov registry.
Key Research Mechanisms — Retatrutide 40mg (R&D Only)
- Sustained triple GLP-1/GIP/Glucagon agonism: 4×10mg doses enabling multi-administration sustained-phase research protocols across extended experimental timelines — the complete expression of triple-agonist pharmacology
- Dose-dependent energy expenditure: Glucagon receptor-mediated thermogenic energy expenditure is dose-dependent — the 40mg format enables investigation of the full glucagon-driven metabolic effect at sustained compound concentrations
- Hepatic fat oxidation — sustained: Glucagon-driven hepatic fat oxidation across extended research timelines — critical for UK NAFLD/NASH research requiring sustained compound exposure
- Adipose tissue biology — full protocol: Sustained triple-receptor synergistic lipolysis, white-to-beige adipose transition and energy expenditure across multi-administration study designs
- Dose-escalation endpoint: The 40mg format is the standard escalation endpoint for researchers who began with Retatrutide 20mg (R&D Only) initiation protocols
- Comparative sustained dual vs triple agonist: The definitive triple-agonist sustained endpoint — paired with Tirzepatide 40mg (R&D Only) to produce the most mechanistically powerful dual vs triple agonist comparative research design available in UK pre-clinical science
- Weight loss biology — full endpoint: Investigating the complete triple-agonist weight loss mechanism at the sustained dose — most directly referenced to the highest-dose groups in the landmark NEJM Phase 2 retatrutide trial
- Pancreatic and cardiovascular biology: Triple receptor sustained effects on insulin secretion, glucagon suppression, beta-cell function and cardiovascular risk markers across extended experimental protocols
Full Technical Specifications — Retatrutide 40mg (R&D Only)
| Product Name | Retatrutide 40mg (R&D Only) — Alluvi Healthcare |
| Supplier | Alluvi Healthcare UK |
| Active Compound | Retatrutide |
| Also Known As | Retratrutide · Alluvi reta pen · Reta pen UK · Reta UK · Reta jab · Alluvi retatrutide · 40mg retatrutide |
| Compound Class | Triple GLP-1 / GIP / Glucagon Receptor Agonist |
| Total Per Pen | 40mg |
| Dose Structure | 4 × 10mg doses (precision click-dial mechanism) |
| Micro-Dose Increments | 2.5mg · 5mg · 7.5mg · 10mg per dose |
| Delivery Format | Pre-filled subcutaneous injection pen |
| Needles Included | 6 × fine-gauge subcutaneous pen needles |
| Purity Standard | ≥98% — independent third-party analytical verification |
| Certificate of Analysis | Batch-specific COA included with every order |
| Storage | Refrigerated 2–8°C · Away from direct light · Do not freeze |
| Dispatch | Within 48 hours — cold-chain insulated · UK domestic stock |
| Delivery | All UK addresses — mainland + highlands |
| Price | £219.99 — use code alluvicare26 for 35% off |
| Research Application | Sustained-phase triple GLP-1/GIP/Glucagon agonism · Weight loss biology · Multi-administration protocols · Comparative R&D |
| Regulatory Status | R&D use only — not MHRA licensed · Not for human consumption |
Retatrutide 40mg vs 20mg R&D — The Protocol Decision
| Feature | Retatrutide 20mg (R&D Only) | Retatrutide 40mg (R&D Only) |
|---|---|---|
| Total per pen | 20mg | 40mg |
| Doses per pen | 2 × 10mg | 4 × 10mg |
| Protocol position | Initiation phase · Dose-response baseline | Sustained phase · Full endpoint · Multi-administration |
| Best for | Starting triple-agonist R&D · Lower-dose comparative studies | Higher-dose sustained protocols · Extended timelines · NEJM trial-referenced dose range |
| Price | £139.99 | £219.99 |
| COA ≥98% | ✓ Yes | ✓ Yes |
| 48hr UK dispatch | ✓ Yes | ✓ Yes |
| Order | Buy 20mg → | Buy 40mg → |
Retatrutide 40mg R&D vs Tirzepatide 40mg R&D — Sustained Dual vs Triple
| Feature | Retatrutide 40mg R&D | Tirzepatide 40mg R&D |
|---|---|---|
| Receptor targets | GLP-1 + GIP + Glucagon (triple) | GLP-1 + GIP (dual) |
| Glucagon agonism | ✓ Yes — thermogenic + lipolytic | ✗ No |
| Hepatic fat oxidation | ✓ Glucagon-driven sustained | Limited |
| Energy expenditure | ✓ Dose-dependent glucagon mechanism | GLP-1 only |
| Doses per pen | 4 × 10mg | 4 × 10mg |
| NEJM trial data | Up to 24.2% weight loss at 48 weeks | Up to 22.5% at 72 weeks |
| COA ≥98% | ✓ Yes | ✓ Yes |
| 48hr UK dispatch | ✓ Yes | ✓ Yes |
| Order | Buy Retatrutide 40mg → | Buy Tirzepatide 40mg → |
Retatrutide 40mg R&D — UK Source Comparison
| Feature | Alluvi Healthcare | Synedica Retatrutide | VLS Retatrutide |
|---|---|---|---|
| Format | Pre-filled pen | Vial | Vial / pen |
| Dose per pen | 40mg (4×10mg) | Variable | Variable |
| UK Domestic Stock | ✓ 48hr dispatch | Varies | Varies |
| COA ≥98% | ✓ Independent | Varies | Varies |
| WhatsApp Support | ✓ +44 7537 823566 | Email only | Limited |
| Discount Code | ✓ alluvicare26 — 35% off | — | — |
| Is it legit? | ✓ See Alluvi Healthcare reviews | Community verified | Community reported |
| Order | Buy Now → | — | — |
Read our full Synedica vs Alluvi comparison, retatrutide 40mg pen price UK guide and Alluvi Healthcare legitimacy review on the Alluvi Healthcare research blog.
Research Applications — What UK Labs Are Investigating
- Sustained-phase triple-agonist research: 4×10mg doses enabling multi-administration sustained protocols — the full expression of triple GLP-1/GIP/Glucagon pharmacology across extended experimental timelines
- Dose-escalation endpoint: The definitive higher-dose endpoint for researchers who began with Retatrutide 20mg (R&D Only) initiation protocols
- Weight loss R&D — sustained endpoint: Investigating triple-agonist weight loss mechanisms most directly referenced to the highest-dose groups in the landmark NEJM Phase 2 retatrutide trial (up to 24.2% at 48 weeks)
- Hepatic steatosis and NAFLD/NASH: Glucagon-driven sustained hepatic fat oxidation across extended research timelines in metabolic liver disease models
- Adipose tissue — sustained protocols: Triple-receptor synergistic lipolysis, white-to-beige adipose transition and energy expenditure in multi-administration study designs
- Sustained comparative dual vs triple agonist: Definitive triple-agonist sustained endpoint alongside Tirzepatide 40mg (R&D Only) — the most powerful comparative metabolic R&D design in UK pre-clinical science
- Compound pharmacy retatrutide UK alternative: UK researchers comparing compound pharmacy retatrutide UK options consistently find Alluvi Healthcare offers superior pen format, faster domestic dispatch and more competitive 40mg pricing
- Wholesale R&D supply: For laboratories requiring bulk retatrutide 40mg UK supply, visit our Alluvi Healthcare wholesale page
Is Alluvi Healthcare Legit for Retatrutide 40mg R&D?
The most searched question before purchasing retatrutide 40mg UK is “is Alluvi Healthcare legit?” — and the answer is yes. Alluvi Healthcare is a legitimate UK-based supplier of research-grade retatrutide and peptide compounds. All products are clearly labelled for R&D use only, independently COA verified at ≥98% purity, dispatched from UK domestic stock within 48 hours and supported by a responsive research team via WhatsApp +44 7537 823566. Community feedback across UK research forums, Reddit discussions and Alluvi Healthcare reviews consistently confirms product quality, fast dispatch and responsive support.
How to Buy Retatrutide 40mg UK — Step by Step
- Visit alluviukshop.co.uk/shop and select Retatrutide 40mg (R&D Only)
- Consider adding Retatrutide 20mg (R&D Only) for a complete initiation-to-sustained protocol, or Tirzepatide 40mg (R&D Only) for a sustained dual vs triple agonist comparative R&D design
- Apply code alluvicare26 at checkout for 35% off — applied automatically on first orders
- Receive within 48 hours — cold-chain dispatched in discreet unmarked packaging with full tracking
- Refrigerate immediately at 2–8°C and verify the batch COA before beginning your R&D protocol
Storage & Handling
- Refrigerate immediately on receipt at 2–8°C
- Do not freeze — freezing permanently degrades retatrutide’s molecular structure
- Protect from direct light — store in original packaging inside the refrigerator
- Do not shake or agitate — handle gently at all times
- Verify COA batch number before beginning any R&D protocol
- Note the expiry date printed on the pen body and outer packaging
- Inspect before use — if cloudy, discoloured or contains particulates do not use. Contact Alluvi Healthcare via WhatsApp immediately
Explore the Complete Alluvi Healthcare R&D Range
- Retatrutide 20mg (R&D Only) — Initiation phase · Triple agonist · 2×10mg · ≥98% COA · £139.99
- Tirzepatide 40mg (R&D Only) — Sustained dual GLP-1/GIP · 4×10mg · ≥98% COA
- Tirzepatide 20mg (R&D Only) — Initiation dual GLP-1/GIP · 2×10mg · ≥98% COA
- BPC-157 TB500 40mg (R&D Only) — Recovery & repair · Dual peptide · 4×10mg
- Glow 70mg (R&D Only) — GHK-Cu + BPC-157 + TB-500 · Skin · hair · cellular repair
- NAD+ 1000mg (R&D Only) — Brain cellular repair · Anti-ageing · 2×500mg
- Wholesale R&D Supply — Bulk retatrutide 40mg UK for laboratories
- Alluvi Healthcare Blog — Retatrutide UK guides, price comparisons and R&D sourcing articles
⚠️ R&D Use Only — Legal Disclaimer: Retatrutide 40mg (R&D Only) is supplied exclusively for legitimate scientific laboratory research, analytical testing and formulation development. It is not licensed as a medicine by the MHRA or any other regulatory body and is not intended for human consumption, self-administration, veterinary use or clinical application outside of authorised clinical trials. By purchasing, the buyer confirms they are a qualified researcher aged 18 or above operating within a legitimate research context in full compliance with all applicable UK regulations. Alluvi Healthcare accepts no liability for misuse outside of these stated conditions. For regulatory guidance visit MHRA.gov.uk. For clinical context visit NICE.org.uk.
Reviews
There are no reviews yet.